Gilead Sciences, Inc. $GILD Shares Sold by Lombard Odier Asset Management Europe Ltd

Lombard Odier Asset Management Europe Ltd decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,396 shares of the biopharmaceutical company’s stock after selling 7,604 shares during the quarter. Lombard Odier Asset Management Europe Ltd’s holdings in Gilead Sciences were worth $1,728,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of GILD. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares during the last quarter. State Street Corp lifted its holdings in shares of Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after purchasing an additional 1,195,269 shares during the period. Bank of America Corp DE boosted its position in shares of Gilead Sciences by 15.2% in the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Norges Bank purchased a new position in Gilead Sciences in the 4th quarter worth about $2,617,152,000. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of analyst reports. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Wednesday, May 20th. Truist Financial dropped their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Citigroup boosted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Daiwa Securities Group reduced their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Finally, Royal Bank Of Canada decreased their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $158.33.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the sale, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the transaction, the insider owned 124,234 shares in the company, valued at $15,395,077.28. This trade represents a 2.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 77,000 shares of company stock valued at $9,978,740 in the last quarter. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $129.31 on Monday. The stock has a market cap of $160.55 billion, a PE ratio of 17.62 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The stock’s 50-day moving average is $129.55 and its two-hundred day moving average is $135.62.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.